To include your compound in the COVID-19 Resource Center, submit it here.

Genzyme acquiring SangStat

GENZ will buy SANG for about $600 million in cash, or $22.50 per share. The take out price is a 45% premium to SANG's Friday close at $15.48. GENZ

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE